Hyderabad, Mar 27 (TNT): Hetero, a leading global pharmaceutical compny, on Friday announced the export launch of its generic semaglutide injection portfolio to expand access to treatments for type 2 diabetes and obesity across global markets.
In a release, the Hyderabad based pharma company said the injectable therapies will be marketed under the brand names Truglyx, Rolmodl and Moto G, with initial rollouts underway in Africa, Asia and the Middle East.
The company plans a phased expansion to over 75 countries as part of its multi-year global strategy.
Semaglutide belongs to the GLP-1 class of therapies used in managing diabetes and weight-related conditions.
The launch aims to improve access to affordable, high-quality cardio-metabolic treatments in emerging markets, the company said.
The company is currently awaiting approval from the Central Drugs Standard Control Organisation (CDSCO) for launch in India, following completion of clinical trials.
The domestic rollout is expected after regulatory clearance.
Managing Director Vamsi Krishna Bandi said the company has developed a global-quality product platform for complex generics and will leverage its commercial network across Asia, the Middle East, Africa and Latin America to expand access to therapies.
The portfolio will be available in multi-dose disposable pen devices across multiple strengths, including 0.25 mg, 0.5 mg, 1 mg, 2 mg, 1.7 mg and 2.4 mg, supporting flexible and patient-centric dosing for diabetes and weight management.
Focusing on the development, manufacturing and commercialization of Active pharmaceutical Ingredients (APIs) and generic formulations, the company operates in more than 145 countries and is a trusted partner to multinational pharmaceutical companies and global procurement agencies.
TNT TS
Leave a Reply